Astria Therapeutics (NASDAQ:ATXS) Shares Up 5.5% – Still a Buy?

Astria Therapeutics, Inc. (NASDAQ:ATXS) shares traded up 5.5% on Wednesday . The stock traded as high as $10.73 and last traded at $10.72. 431,898 shares traded hands during trading, a decline of 27% from the average session volume of 594,279 shares. The stock had previously closed at $10.16.

Analyst Ratings Changes

A number of brokerages have issued reports on ATXS. Oppenheimer raised their price target on shares of Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Thursday, November 14th. HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of Astria Therapeutics in a research note on Tuesday. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Astria Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $25.60.

Astria Therapeutics Price Performance

The company’s fifty day simple moving average is $10.87 and its 200 day simple moving average is $10.68.

Hedge Funds Weigh In On Astria Therapeutics

A number of institutional investors have recently bought and sold shares of ATXS. FMR LLC grew its holdings in shares of Astria Therapeutics by 29.2% during the 3rd quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock worth $86,123,000 after acquiring an additional 1,767,714 shares during the period. Vestal Point Capital LP grew its stake in Astria Therapeutics by 23.1% in the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock worth $44,040,000 after purchasing an additional 750,000 shares during the period. Sofinnova Investments Inc. bought a new position in Astria Therapeutics in the second quarter worth $552,000. ClariVest Asset Management LLC purchased a new position in Astria Therapeutics during the second quarter valued at $731,000. Finally, Intech Investment Management LLC bought a new stake in shares of Astria Therapeutics during the 3rd quarter valued at $228,000. 98.98% of the stock is owned by institutional investors.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.